Furthermore, human alpha-synuclein-overexpressing transgenic mice, a model of early PD, demonstrate elevated dopamine uptake rates and more pronounced effects of DAT inhibitors on evoked extracellular dopamine concentrations [88]. Here, SLC6A3 is linked to Parkinson disease.